On May 23, Nasdaq Provided Notice To Seelos Therapeutics Inc That It Has Not Regained Compliance With Rule 5550(A)(2)
Portfolio Pulse from Happy Mohamed
Seelos Therapeutics Inc. received a notice from Nasdaq on May 23 stating that it has not regained compliance with Rule 5550(a)(2).
May 26, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Seelos Therapeutics Inc. has not regained compliance with Nasdaq Rule 5550(a)(2), which may negatively impact its stock price.
Seelos Therapeutics Inc. has not regained compliance with Nasdaq Rule 5550(a)(2). This news may negatively impact the company's stock price as it indicates potential issues with the company's financial health or performance. Investors may perceive this as a risk and sell their shares, leading to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100